---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095059"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:04:38.054748+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics Q2 net loss $34.7M; cash $179.8M; clinical milestones for SMARCA2 and CDK9 programs

## Summary
- Net loss $34.7M ($0.46/share) vs $30.4M ($0.54/share) in Q2 2023; R&D expense rose to $29.5M from $25.0M.
- Cash, equivalents and marketable securities $179.8M at June 30, 2024; runway extended into 2026.
- PRT3789 interim Phase 1 data selected for oral presentation at ESMO Congress 2024 (Sept 13).
- IND authorized for oral SMARCA2 degrader PRT7732; Phase 1 start expected H2 2024.
- Clinical collaboration with Merck to evaluate PRT3789 in combination with KEYTRUDA; Phase 2 start expected Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-095059
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017024095059/0000950170-24-095059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017024095059/prld-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095059
- JSON: https://secwatch.observer/filing/0000950170-24-095059.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.